Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (Chemobrain)

Broadly speaking, the goal of this study is to better understand the influence of chemotherapy treatment on the cognitive and neural mechanisms underlying human behavior. Extant literature lacks diversity in studied cancer populations and treatment protocols, and provides limited understanding of the cognitive abilities that are impaired by chemotherapy. To overcome these limitations, this study will employ a sophisticated battery of tests on an understudied cancer population. Eligible participants will either be patients diagnosed with hematological malignancy (HM) or demographically matched healthy control patients.

After HM diagnosis and treatment protocols have been established, patients will be inducted into the longitudinal study comprised of three visits: 1) after diagnosis but prior to chemotherapy treatment (baseline), 2) after one treatment cycle (one month post-baseline), and 3) after three treatment cycles (three months post-baseline). Patients will undergo a test battery designed to measure specific behavioral and neural mechanisms of attention; tests will either be computer-based cognitive tasks or simulated driving tests that immerse patients into virtual driving scenarios. During each test, EEG will be concurrently measured through non-invasive scalp electrophysiology recordings; EEG recordings will reveal underlying neural mechanisms affected by chemotherapy. Additionally, neuropsychological tests of vision, attention, and memory will be administered, as well as questionnaires to evaluate health, mobility, and life space. Finally, blood samples will be collected to examine levels of circulating inflammation-specific proteins typically present in cancer patients. This study will allow us to better understand the mechanisms through which chemotherapy influences cognitive performance. Results from this study will influence the administration of chemotherapy treatments so that patients can continue to receive the highest medical care while maintaining optimal cognitive abilities and quality of life.

Study Overview

• Status: Completed
• Conditions: Acute Myeloid Leukemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Mild Cognitive Impairment; Myelodysplastic Syndrome; Acute Lymphoid Leukemia; Effects of Chemotherapy; Non-hodgkin Lymphoma

Detailed Description

The broad goal of this research project is to develop a core set of biomarkers for chemotherapy-related cognitive impairment (or chemobrain). Clinical studies have documented mild cognitive impairment in chemotherapy patients most frequently within the domains of attention and memory, though impairments have been observed across a broad range of cognitive abilities. In addition, neuroimaging studies have demonstrated chemotherapy-related structural and functional changes in distributed cortical areas, including regions of the fronto-parietal attention network. While these studies suggest chemotherapy treatment negatively impacts patient health and cognitive function, it remains unclear how chemotherapy affects neural mechanisms of cognitive abilities. Current literature is limited in four major ways: (1) most research has focused on breast cancer populations, providing little insight into impact of tumor type, (2) few studies have examined the parametric effects of chemotherapy toxicity, (3) neuropsychological exams provide weak resolution of specific cognitive functions, and (4) neural factors associated with cognitive impairment are difficult to dissociate from non-neural (e.g. psychosocial) factors. To overcome these central limitations, the investigators propose a one-year longitudinal study that aims to systematically examine the influence of cancer stage and treatment toxicity on mild cognitive impairment observed in hematological malignancy (HM) patients by implementing a core battery of behavioral and neural measures of attention.

Our specific aims (SA) are to:

SA1: Quantify chemotherapy-related impairments of attention-specific processes in HM patients.

H1a: No difference in behavioral measures of attention will be observed across HM groups prior to treatment, and HM groups will perform worse than healthy controls.

H1b: Exposure to chemotherapy will predict behavioral impairments of attention, and the magnitude of impairment will be linked with treatment toxicity.

SA2: Quantify electrophysiological measures of attention-specific processes and determine the link between chemotherapy-related impairments in neural activity and cognitive ability.

H2a: No difference in electrophysiological measures of attention will be observed across HM and healthy control groups prior to treatment.

H2b: Exposure to chemotherapy will predict functional impairments in electrophysiological measures of attention, and the magnitude of impairment will be linked with treatment toxicity.

H2c: Chemotherapy-related impairment in neural measures of attention will be predicted by concurrent impairments in behavioral measures of attention (as in H1b).

SA3: Implement controlled simulations of on-road driving scenarios that probe specific attention processes to determine the impact of chemotherapy on complex real-world behavior.

H3a: No difference in driving performance will be observed across HM groups prior to treatment, and driving performance will be better in healthy controls compared to HM patients.

H3b: Exposure to chemotherapy will predict greater impairment in simulated driving performance, and the magnitude of impairment will be linked with treatment toxicity.

H3c: Impairments in behavioral (as in H1a) and neural measures (as in H2a) of attention will predict greater impairment in simulated on-road driving performance.

Our empirical approach will allow us to more rigorously study the neural mechanisms of chemotherapy-related cognitive impairment. The current proposal aims to extend previous research by longitudinally investigating an understudied cancer population whose constituents are assigned to a treatment group at diagnosis, thus providing sufficient experimental control for examining parametric effects of cancer burden and treatment toxicity on specific mechanisms of attention. Results obtained from this study will be critical to understanding risk factors associated with chemotherapy, which will allow clinicians to make informed treatment recommendations in order to reduce the likelihood of cognitive impairment and maintain the highest quality of life possible for the ever-increasing cancer survivor population.

• Study Type: Observational
• Enrollment (Actual): 45

Contacts and Locations

Study Locations

• United States
  • Nebraska
    • Omaha, Nebraska, United States, 68132
      • University of Nebraska Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The 2008 World Health Organization (WHO) classification is used to diagnose MDS. Patients diagnosed with MDS are stratified into one of five risk categories, based on a prognostic score calculated according to the revised International Prognostics Scoring System (IPSS-R): very-low risk, low risk, intermediate risk, high risk, and very-high risk. IPSS-R scores are estimated from percent of bone marrow blasts, number and depth of cytopenias, and presence of specific cytogenetic abnormalities, collectively reflecting the total number of risk factors.

Description

Inclusion criteria:

• HM diagnosis
• scheduled to receive treatment based on risk classification
• between 19 to 80 years of age-
• normal or corrected-to-normal vision
• matched to HM patient demographics (healthy controls)

Exclusion criteria:

• non-HM non-cutaneous cancer diagnosis (patients with localized skin cancer may not be excluded)
• prior radiation or chemotherapy treatment
• HM cancer diagnosis (healthy controls)

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
HM - Chemotherapy; Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
HM - No Chemotherapy; Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
Healthy Controls; Study participants that are demographically matched to HM study patients and meet all inclusion criteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline Capture Task Performance at 1- and 3- Months	Response time - measured as the time required to respond to a target hidden among distractor items - is the primary outcome measure of the capture task. Proportional response time was calculated by subtracting mean response time in the neutral condition from response time in the capture condition, and dividing that number by the standard deviation of response time across conditions. Changes in proportional response time across study visits is reported. Positive values correspond to an increase in response time and negative values correspond to a decrease in response time.	Collected at Study Induction, 1 month after Study Induction, 3 months after Study Induction
Change From Baseline N2pc Amplitude at 1- and 3- Months	Electrophysiological component that measures allocation of attentional resources	Collected at Study Induction, 1 month after Study Induction, 3 months after Study Induction
Change From Baseline Filter Task Performance at 1- and 3- Months	Response accuracy - measured as the proportion of correct trials - is the primary outcome measure of the filter task. Changes in response accuracy were calculated by subtracting response accuracy at 1-month and 3-months from baseline response accuracy. Positive values correspond to an increase in accuracy and negative values correspond to a decline in accuracy.	Collected at Study Induction, 1 month after Study Induction, 3 months after Study Induction
Change From Baseline CDA Amplitude at 1- and 3- Months	Electrophysiological component that measures online storage load	Collected at Study Induction, 1 month after Study Induction, 3 months after Study Induction

Collaborators and Investigators

• Sponsor: University of Nebraska
• Investigators: Principal Investigator: Vijaya Bhatt, MD, University of Nebraska

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2016
• Primary Completion (Actual): December 11, 2017
• Study Completion (Actual): March 15, 2018

Study Registration Dates

• First Submitted: April 22, 2016
• First Submitted That Met QC Criteria: May 5, 2016
• First Posted (Estimated): May 10, 2016

Study Record Updates

• Last Update Posted (Actual): September 29, 2023
• Last Update Submitted That Met QC Criteria: September 21, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Neurocognitive Disorders; Disease Attributes; Bone Marrow Diseases; Hematologic Diseases; Hemorrhagic Disorders; Myeloproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Neoplasms, Plasma Cell; Cognition Disorders; Leukemia, B-Cell; Drug-Related Side Effects and Adverse Reactions; Chronic Disease; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia; Leukemia, Myeloid; Cognitive Dysfunction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Chemotherapy-Related Cognitive Impairment
• Other Study ID Numbers: 0137-16-EP

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED